Литература. 
Современные принципы антитромбоцитарной терапии у больных с ишемической болезнью сердца. 
Часть 2. Переносимость и возможные побочные эффекты

1. Вікторов О.П. Ацетилсаліцилова кислота та клопідогрель: раціональність комбінованої фармакотерапії // Медицина неотложных состояний. 2008. № 4. С. 39−44.

2. Волков В. И., Рябуха В. В., Запровальная О. Е., Ладный А. И. Диагностика резистентности к аспирину у больных с ишемической болезнью сердца // Укр. кардіол. журн. 2006. № 3. С. 36−39.

3. Воронков Л. Г. Место аспирина в профилактике сердечно-сосудистых осложнений: 16 вопросов и ответов. K., 2008. 22 с.

4. Нетяженко В. З., Мальчевська Т. Й. «Аспірин» як доказ ефективності антитромбоцитарної стратегії в первинній та вторинній профілактиці серцево-судинних захворювань // Серце і судини. 2005. № 3. С. 19−26.

5. Antithrombotic Trialist’s Collaboration. Collaborative meta-analysis of randomised trials of antiplatelat therapy for prevention of death, myocardial infarction, and stroke in high risk patients // Brit. Med. J. 2002. Vol. 324. P. 71−76.

6. Aspirin for the primary prevention of cardiovascular events: recommendation and rationale // Ann. Intern. Med. 2002. Vol. 136. P. 157−160.

7. Balsano F., Rizzon P., Violi F. et al. Studio della Ticlopidina nell’Angina Instabile Group. Antiplatelet treatment with ticlopidine in unstable angina: a controlled multicenter clinical trial // Circulatin. 1990. Vol. 82. P. 17−26.

8. Biondi-Zoccai G. G., Lotrionte M., Agostoni P. et al. Systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50 279 patients at risk for coronary disease // Eur. Heart J. 2006. Vol. 27. P. 2667−2674.

9. Bhatt D.L., Fox K.A., Hacke W. et al. CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events // New Engl. J. Med. 2006. № 20. Vol. 354 (16). P. 1706−1717.

10. Cairns J.A., Gent M., Singer J. et al. Aspirin, sulfin-pyrazone, or both in unstable angina: results of a Canadian multicenter trial // New Engl. J. Med. 1985. Vol. 313. P. 1369−1375.

11. Cairns J.A., Theroux P., Lewis H.D. Jr. et al. Antithrombotic agents in coronary artery disease // Checet. 2001. Vol. 119 (Suppl. 1). P. 228−252.

12. Cambia-Kiely J.A., Gandhi P.J. Possible mechanism of aspirin resistance // J. Thromb. Thrombolysis. 2002. Vol. 13. P. 49−56.

13. Chen W., Lee P., Ng W. et al. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment // J. Amer. Coll. Cardiology. 2004. Vol. 43. P. 1122−1126.

14. Diener H.C., Bogousslavsky J., Brass L.M. et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH) // Lancet. 2004. Vol. 364. P. 331−337.

15. Eikelboom J.W., Hirsh J., Weitz J. et al. Aspirin resistance response // Circulation. 2002. Vol. 106. P. 200−201.

16. Gessner U., Latta G. Assessment of the tolerability of the Aspirin protect 100 by a 2-year postmarketing multicenter, non-blinded, non-controlled surveillance study. 1998 (Bayer).

17. Gum P.A., Kottke-Marchant K., Poggio E.D. et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease // Amer. J. Cardiology. 2001. Vol. 88. P. 230−235.

18. Gum P.A., Kottke-Marchant K., Welsh P.A. et al. A prospective, blinded determination of the natural history of aspirin resis-tance among stable patients with cardiovascular disease // J. Amer. Coll. Cardiology. 2003. Vol. 41. P. 961−965.

19. Grundmann K., Jaschonek K., Kleine B. et al. Aspirin non-responder status in patients with recurrent cerebral ischemic attacks // J. Neurology. 2003. Vol. 250. P. 63−66.

20. Hansson L., Zanchetti A. et al. Effects of intensive blood pressure lowering and low dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial // Lancet. 1998. Vol. 351. P. 1755−1762.

21. Kubler W. The cost effectiveness of platelet aggregation inhibitors in preventing ardiac disease // Eur. Cardioligist J. 2007. Vol. 12 (№ 38). P. 166−181.

22. Langleben D. et al. Effects of the thromboxane synthetase inhibitor and receptor antagonist terbogrel in patients with primary pulmonary hypertension // Amer. Heart J. 2002. Vol. 143.

23. Machi L., Christiaens L., Brabant S. et al. Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate // Thromb. Res. 2002. Vol. 107. Р. 45−49.

24. Nyman I., Larsson H., Wallentin L. Research Group on Instability in Coronary Artery Disease in South-east Sweden Prevention of serious cardiac events by low-dose aspirin in patients with silent myocardial ischaemia // Lancet. 1992. Vol. 340. P. 497−501.

25. Patrono C., Bachman F., Baigent C. et al. Expert Consensus Document on the Use of Antiplatelet Agents // Eur. Heart J. 2004. Vol. 25. P. 176−181.

26. Petrosky D. Endoscopic comparison of various aspirin preparations gastric mucosal adaptability to aspirin restudied // Curr. Ther. Res. 1989. Vol. 45. P. 945−954.

27. Sanmuganathan P. S., Ghahramani P., Jackson P.R. et al. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials // Heart. 2001. Vol. 85. P. 265−271.

28. Schiffer B., Schiffer E., Hilfiker-Kbeiner D. et al. Expression of angiotensin II and interleukin-6 in human coronary atherosclerotic plaques: potential implication for inflammation and plaque instability // Circulation. 2000. Vol. 101. P. 1372−1378.

29. Soyka R., Guth B.D., Weisenberger H.M. et al. Guanidine derivatives as combined thromboxane A2 receptor antagonists and synthase inhibitors // J. Med. Chem. 1999. Vol. 42. P. 1235−1249.

30. The RAPT Trial Investigators. Randomized trial of ridogrel, a combined thromboxane A2 synthase inhibitor and thromboxane A2 prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction. The Ridogrel Versus Aspirin Patency Trial (RAPT) // Circulation. 1994. Vol. 89. P. 588−595.

31. Theroux P., Ouimet H., McCans J. et al. Aspirin, heparin, or both to treat acute unstable angina // New Engl. J. Med. 1988. Vol. 319. P. 1105−1111.

32. Van Gijn J., Algra A. Aspirin and stroke prevention // Thromb Res. 2003. Vol. 110. P. 349−353.

33. Wang T.H., Bhatt D.L., Topol E.J. Aspirin and clopidogrel resistance: an emerging clinical entity // Eur. Heart J. 2006. Vol. 27. P. 647−654.